Paper Details

  1. Home
  2. Paper Details

The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.

Author: ForbesJohn F

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

The Breast International Group 1-98 trial (BIG 1-98) found that letrozole significantly increased disease-free survival (DFS) compared to tamoxifen in postmenopausal women with early breast cancer. The advantage for letrozole was particularly evident in women at increased risk of recurrence. Letrozole was generally well-tolerated and associated with fewer deaths than tamoxifen.
Paper Details　
Original Abstract of the Article :
Letrozole has proven efficacious in a variety of therapeutic scenarios, including that of extended adjuvant therapy following 5 years of tamoxifen treatment in postmenopausal women with estrogen-receptor-positive early breast cancer. The Breast International Group 1-98 trial (BIG 1-98) is the first ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/j.seminoncol.2006.03.026

データ提供：米国国立医学図書館（NLM）

Letrozole: A New Oasis in the Desert of Breast Cancer

The fight against breast cancer is a long and arduous journey, like traversing a vast desert. This study, like a beacon of hope in the desert, investigates the effectiveness of letrozole, an aromatase inhibitor, in the treatment of early breast cancer. The researchers, driven by the desire to improve patient outcomes, conducted a clinical trial comparing letrozole to tamoxifen, a standard treatment for hormone-responsive breast cancer. Their findings, like a hidden spring in the desert, reveal that letrozole significantly improved disease-free survival, reduced distant recurrences, and prolonged time to distant metastasis compared to tamoxifen, offering a promising new treatment option for postmenopausal women with early breast cancer. The researchers also evaluated the safety of letrozole, noting that it was generally well-tolerated and associated with a similar frequency of serious side effects as tamoxifen.

A New Era of Treatment

The study demonstrates the efficacy of letrozole in treating early breast cancer, offering a new era of treatment options for postmenopausal women. The significant improvements in disease-free survival and reduced risk of distant recurrences provide a beacon of hope for those battling this disease, offering a chance to reclaim their health and navigate the challenges of breast cancer with increased confidence.

Navigating the Desert of Treatment Options

The landscape of breast cancer treatment is constantly evolving, with new and innovative approaches emerging. This research provides valuable insights into the potential benefits and risks of letrozole, offering a guide for healthcare providers and patients as they navigate the complex journey of breast cancer treatment.

Dr.Camel's Conclusion

This study is like discovering a new oasis in the desert of breast cancer treatment - offering a source of hope and a new path toward better outcomes. The efficacy and safety profile of letrozole provide a valuable addition to the treatment arsenal, empowering healthcare professionals and patients to make informed decisions and navigate the challenges of breast cancer with renewed optimism.

Date :
  1. Date Completed 2006-07-06
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

16730270

DOI: Digital Object Identifier

10.1053/j.seminoncol.2006.03.026

Related Literature

Article Analysis
・Effects of letrozole
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.